{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:54Z","timestamp":1789584894502,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-025-00250-y","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:02:44Z","timestamp":1747260164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET\/CT"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-2370","authenticated-orcid":false,"given":"Hannes","family":"Leupe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloefar","family":"Ahmadi Bidakhvidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bliede","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Jentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Lybaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Geboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Stroobants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Verslype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-1577","authenticated-orcid":false,"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"250_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/cancers14010129","volume":"14","author":"NA Bidakhvidi","year":"2022","unstructured":"Bidakhvidi NA, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P et al (2022) Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel) 14:129","journal-title":"Cancers (Basel)"},{"key":"250_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C et al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F\u2013DOPA. Eur J Nucl Med Mol Imaging 44:1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"250_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/medicina58070952","volume":"58","author":"J Cummings","year":"2022","unstructured":"Cummings J, Kinney J (2022) Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation. Medicina 58:952","journal-title":"Medicina"},{"key":"250_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P et al (2016) 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med 57:872\u2013878","journal-title":"J Nucl Med"},{"key":"250_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2967\/jnumed.116.179192","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M et al (2017) 68Ga-DOTATATE PET\/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med 58:307\u2013311","journal-title":"J Nucl Med"},{"key":"250_CR6","unstructured":"Food and Drug Administration. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff DRAFT GUIDANCE. 2018. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"250_CR7","volume-title":"Handbook of inter-rater reliability: how to measure the level of agreement between two or multiple raters","author":"KL Gwet","year":"2001","unstructured":"Gwet KL (2001) Handbook of inter-rater reliability: how to measure the level of agreement between two or multiple raters. Stataxis Publishing Company, Gaithersburg"},{"key":"250_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15020439","volume":"15","author":"A Haeger","year":"2023","unstructured":"Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N et al (2023) Al[18F]F-NOTA-octreotide is comparable to [68Ga]Ga-DOTA-TATE for PET\/CT imaging of neuroendocrine tumours in the Latin-American population. Cancers (Basel) 15:1\u201311","journal-title":"Cancers (Basel)"},{"key":"250_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C (2019) 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on krenning scores and effect of tumor burden. J Nucl Med 60:1266\u20131269","journal-title":"J Nucl Med"},{"key":"250_CR10","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.7150\/thno.96762","volume":"14","author":"G Hou","year":"2024","unstructured":"Hou G, Cheng X, Yang Y, Zhao D, Wang G, Zhao H et al (2024) Diagnostic performance and clinical impact of 18F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: a prospective single-center study. Theranostics 14:3213\u20133220","journal-title":"Theranostics"},{"key":"250_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-021-00797-4","volume":"11","author":"J Hou","year":"2021","unstructured":"Hou J, Long T, He Z, Zhou M, Yang N, Chen D et al (2021) Evaluation of 18F Alf NOTA octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET\/CT. EJNMMI Res 11:55","journal-title":"EJNMMI Res"},{"key":"250_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P et al (2017) Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58:451\u2013457","journal-title":"J Nucl Med"},{"key":"250_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"250_CR14","doi-asserted-by":"publisher","first-page":"175883592311891","DOI":"10.1177\/17588359231189133","volume":"15","author":"G Lens","year":"2023","unstructured":"Lens G, AhmadiBidakhvidi N, Vandecaveye V, Grauwels S, Laenen A, Deckers W et al (2023) Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET\/CT and PET\/MRI. Ther Adv Med Oncol 15:17588359231189132","journal-title":"Ther Adv Med Oncol"},{"key":"250_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C et al (2023) 18F-labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use. J Nucl Med 64:835\u2013841","journal-title":"J Nucl Med"},{"key":"250_CR16","doi-asserted-by":"publisher","first-page":"e13420","DOI":"10.1111\/jne.13420","volume":"36","author":"H Leupe","year":"2024","unstructured":"Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J et al (2024) Clinical impact of using [18F]AlF-NOTA-octreotide PET\/CT instead of [68Ga]Ga-DOTA-SSA PET\/CT: secondary endpoint analysis of a multicenter, prospective trial. J Neuroendocrinol 36:e13420. https:\/\/doi.org\/10.1111\/jne.13420","journal-title":"J Neuroendocrinol"},{"key":"250_CR17","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM (2018) Somatostatin receptor PET ligands\u2014the next generation for clinical practice. Am J Nucl Med Mol Imaging 8:311\u2013331","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"250_CR18","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","volume":"46","author":"E Pauwels","year":"2019","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J et al (2019) Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging 46:2398\u20132399","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"250_CR19","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J et al (2020) [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging 47:3033\u20133046","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"250_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L et al (2023) 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTA-TATE\/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med 64:632\u2013638","journal-title":"J Nucl Med"},{"key":"250_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2967\/jnumed.110.083741","volume":"52","author":"J Ruf","year":"2011","unstructured":"Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F et al (2011) 68Ga-DOTATOC PET\/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 52:697\u2013704","journal-title":"J Nucl Med"},{"key":"250_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G et al (2020) Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem 5:1\u201323","journal-title":"EJNMMI Radiopharm Chem"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-025-00250-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:02:47Z","timestamp":1747260167000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-025-00250-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1186\/s41824-025-00250-y","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Ethische Commissie Onderzoek UZ\/KU Leuven S63678) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study (NCT03883776).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from all participants, with clear communication that the study's findings and data would be published in a scientific journal. All participants agreed to this condition.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No conflicts of interest (CoIs) relevant to this work exist. Nonrelated potential CoIs include: CMD is\/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy. His institution has received travel fees from: GE Healthcare, Sirtex. Timon Vandamme received consultancy fees from AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, Nordic Pharma, Novartis, Roche, Sirtex, Servier, Takeda; research funding (institutional) from Ipsen and Novartis; support for travel\/accomodation from Ipsen, AstraZeneca and Servier. KG received consultancy fees from Bayer, Novartis, Telix Pharmaceuticals, GE Healthcare, Lightpoint, Blue Earth Diagnostics, Merck Sharp & Dome, PSI CRO.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}